Average 0 7 0 7 O
nausea 8 14 8 14 B-clinical_variable
numeric 15 22 15 22 I-clinical_variable
rating 23 29 23 29 I-clinical_variable
scale 30 35 30 35 I-clinical_variable
> 36 37 36 37 O
= 37 38 37 38 O
4/10 39 43 39 43 B-lower_bound
over 44 48 44 48 O
the 49 52 49 52 O
past 53 57 53 57 O
5 58 59 58 59 O
days 60 64 60 64 O
at 65 67 65 67 O
screening 68 77 68 77 O

Calculated 0 10 78 88 O
creatinine 11 21 89 99 B-clinical_variable
clearance 22 31 100 109 I-clinical_variable
can 32 35 110 113 O
be 36 38 114 116 O
done 39 43 117 121 O
within 44 50 122 128 O
14 51 53 129 131 B-upper_bound
days 54 58 132 136 I-upper_bound
of 59 61 137 139 O
study 62 67 140 145 O
enrollment 68 78 146 156 O

Clinical 0 8 157 165 O
evidence 9 17 166 174 O
of 18 20 175 177 O
bowel 21 26 178 183 B-chronic_disease
obstruction 27 38 184 195 I-chronic_disease
at 39 41 196 198 O
the 42 45 199 202 O
time 46 50 203 207 O
of 51 53 208 210 O
study 54 59 211 216 O
enrollment 60 70 217 227 O

Continuation 0 12 228 240 O
of 13 15 241 243 O
over 16 20 244 248 B-treatment
- 20 21 248 249 I-treatment
the 21 24 249 252 I-treatment
- 24 25 252 253 I-treatment
counter 25 32 253 260 I-treatment
therapies 33 42 261 270 I-treatment
for 43 46 271 274 O
nausea 47 53 275 281 O
and/or 54 60 282 288 O
vomiting 61 69 289 297 O
during 70 76 298 304 O
the 77 80 305 308 O
study 81 86 309 314 O

Diagnosis 0 9 315 324 O
of 10 12 325 327 O
cancer 13 19 328 334 B-cancer

Expected 0 8 335 343 O
to 9 11 344 346 O
use 12 15 347 350 O
other 16 21 351 356 O
5HT3 22 26 357 361 B-treatment
antagonists 27 38 362 373 I-treatment
or 39 41 374 376 O
NK1 42 45 377 380 B-treatment
antagonists 46 57 381 392 I-treatment
for 58 61 393 396 O
prophylaxis 62 73 397 408 B-treatment
during 74 80 409 415 O
the 81 84 416 419 O
study 85 90 420 425 O

Females 0 7 426 433 B-gender
who 8 11 434 437 O
are 12 15 438 441 B-pregnancy
pregnant 16 24 442 450 I-pregnancy

Karnofsky 0 9 451 460 B-clinical_variable
performance 10 21 461 472 I-clinical_variable
status 22 28 473 479 I-clinical_variable
> 29 30 480 481 O
= 30 31 481 482 O
50 32 34 483 485 B-lower_bound
% 34 35 485 486 I-lower_bound

On 0 2 487 489 O
cytotoxic 3 12 490 499 B-treatment
chemotherapy 13 25 500 512 I-treatment
in 26 28 513 515 O
the 29 32 516 519 O
high 33 37 520 524 O
/ 37 38 524 525 O
moderate 38 46 525 533 O
/ 46 47 533 534 O
low 47 50 534 537 O
emetogenic 51 61 538 548 O
risk 62 66 549 553 O
categories 67 77 554 564 O
or 78 80 565 567 O
oral 81 85 568 572 B-treatment
antineoplastic 86 100 573 587 I-treatment
agents 101 107 588 594 O
in 108 110 595 597 O
the 111 114 598 601 O
high 115 119 602 606 O
or 120 122 607 609 O
moderate 123 131 610 618 O
emetogenic 132 142 619 629 O
risk 143 147 630 634 O
categories 148 158 635 645 O
according 159 168 646 655 O
to 169 171 656 658 O
the 172 175 659 662 O
latest 176 182 663 669 O
National 183 191 670 678 O
Comprehensive 192 205 679 692 O
Cancer 206 212 693 699 O
Network 213 220 700 707 O
( 221 222 708 709 O
NCCN 222 226 709 713 O
) 226 227 713 714 O
guideline 228 237 715 724 O
within 238 244 725 731 O
2 245 246 732 733 B-upper_bound
weeks 247 252 734 739 I-upper_bound
of 253 255 740 742 O
study 256 261 743 748 O
enrollment 262 272 749 759 O

On 0 2 760 762 O
scheduled 3 12 763 772 O
CYP3A4 13 19 773 779 O
substrates 20 30 780 790 O
with 31 35 791 795 O
narrow 36 42 796 802 O
safety 43 49 803 809 O
range 50 55 810 815 O
at 56 58 816 818 O
the 59 62 819 822 O
time 63 67 823 827 O
of 68 70 828 830 O
study 71 76 831 836 O
enrollment 77 87 837 847 O
( 88 89 848 849 O
alfentanil 89 99 849 859 B-treatment
, 99 100 859 860 O
cyclosporine 101 113 861 873 B-treatment
, 113 114 873 874 O
dihydroergotamine 115 132 875 892 B-treatment
, 132 133 892 893 O
ergotamine 134 144 894 904 O
, 144 145 904 905 O
pimozide 146 154 906 914 B-treatment
, 154 155 914 915 O
quinidine 156 165 916 925 B-treatment
, 165 166 925 926 O
sirolimus 167 176 927 936 B-treatment
, 176 177 936 937 O
tacrolimus 178 188 938 948 B-treatment
) 188 189 948 949 O

On 0 2 950 952 O
scheduled 3 12 953 962 O
potent 13 19 963 969 O
CYP3A4 20 26 970 976 O
inducers 27 35 977 985 O
at 36 38 986 988 O
the 39 42 989 992 O
time 43 47 993 997 O
of 48 50 998 1000 O
study 51 56 1001 1006 O
enrollment 57 67 1007 1017 O
( 68 69 1018 1019 O
avasimibe 69 78 1019 1028 B-treatment
, 78 79 1028 1029 O
carbamazepine 80 93 1030 1043 B-treatment
, 93 94 1043 1044 O
phenytoin 95 104 1045 1054 B-treatment
, 104 105 1054 1055 O
rifampin 106 114 1056 1064 B-treatment
, 114 115 1064 1065 O
efavirenz 116 125 1066 1075 B-treatment
, 125 126 1075 1076 O
nevirapine 127 137 1077 1087 B-treatment
, 137 138 1087 1088 O
barbiturates 139 151 1089 1101 B-treatment
, 151 152 1101 1102 O
systemic 153 161 1103 1111 B-treatment
glucocorticoids 162 177 1112 1127 I-treatment
, 177 178 1127 1128 O
modafinil 179 188 1129 1138 B-treatment
, 188 189 1138 1139 O
oxcarbazine 190 201 1140 1151 B-treatment
, 201 202 1151 1152 O
phenobarbital 203 216 1153 1166 B-treatment
, 216 217 1166 1167 O
pioglitazone 218 230 1168 1180 B-treatment
, 230 231 1180 1181 O
rifabutin 232 241 1182 1191 B-treatment
, 241 242 1191 1192 O
St. 243 246 1193 1196 B-treatment
John 247 251 1197 1201 I-treatment
's 251 253 1201 1203 I-treatment
wort 254 258 1204 1208 I-treatment
, 258 259 1208 1209 O
troglitazone 260 272 1210 1222 B-treatment
) 272 273 1222 1223 O

On 0 2 1224 1226 O
scheduled 3 12 1227 1236 O
strong 13 19 1237 1243 B-treatment
or 20 22 1244 1246 I-treatment
moderate 23 31 1247 1255 I-treatment
CYP3A4 32 38 1256 1262 I-treatment
inhibitors 39 49 1263 1273 I-treatment
( 50 51 1274 1275 O
boceprevir 51 61 1275 1285 B-treatment
, 61 62 1285 1286 O
clarithromycin 63 77 1287 1301 B-treatment
, 77 78 1301 1302 O
conivaptan 79 89 1303 1313 B-treatment
, 89 90 1313 1314 O
indinavir 91 100 1315 1324 B-treatment
, 100 101 1324 1325 O
itraconazole 102 114 1326 1338 B-treatment
, 114 115 1338 1339 O
ketoconazole 116 128 1340 1352 B-treatment
, 128 129 1352 1353 O
lopinavir 130 139 1354 1363 B-treatment
/ 139 140 1363 1364 O
ritonavir 140 149 1364 1373 B-treatment
, 149 150 1373 1374 O
mibefradil 151 161 1375 1385 B-treatment
, 161 162 1385 1386 O
nefazodone 163 173 1387 1397 B-treatment
, 173 174 1397 1398 O
nelfinavir 175 185 1399 1409 B-treatment
, 185 186 1409 1410 O
posaconazole 187 199 1411 1423 B-treatment
, 199 200 1423 1424 O
ritonavir 201 210 1425 1434 O
, 210 211 1434 1435 O
saquinavir 212 222 1436 1446 B-treatment
, 222 223 1446 1447 O
telaprevir 224 234 1448 1458 B-treatment
, 234 235 1458 1459 O
telithromycin 236 249 1460 1473 B-treatment
, 249 250 1473 1474 O
voriconazole 251 263 1475 1487 B-treatment
; 263 264 1487 1488 O
amprenavir 265 275 1489 1499 B-treatment
, 275 276 1499 1500 O
aprepitant 277 287 1501 1511 B-treatment
, 287 288 1511 1512 O
atazanavir 289 299 1513 1523 B-treatment
, 299 300 1523 1524 O
ciprofloxacin 301 314 1525 1538 B-treatment
, 314 315 1538 1539 O
darunavir 316 325 1540 1549 B-treatment
/ 325 326 1549 1550 O
ritonavir 326 335 1550 1559 O
, 335 336 1559 1560 O
diltiazem 337 346 1561 1570 B-treatment
, 346 347 1570 1571 O
erythromycin 348 360 1572 1584 B-treatment
, 360 361 1584 1585 O
fluconazole 362 373 1586 1597 B-treatment
, 373 374 1597 1598 O
fosamprenavir 375 388 1599 1612 B-treatment
, 388 389 1612 1613 O
grapefruit 390 400 1614 1624 B-treatment
juice 401 406 1625 1630 I-treatment
, 406 407 1630 1631 O
imatinib 408 416 1632 1640 B-treatment
, 416 417 1640 1641 O
verapamil 418 427 1642 1651 B-treatment
) 427 428 1651 1652 O
within 429 435 1653 1659 O
one 436 439 1660 1663 B-upper_bound
week 440 444 1664 1668 I-upper_bound
of 445 447 1669 1671 O
study 448 453 1672 1677 O
enrollment 454 464 1678 1688 O

Severe 0 6 1689 1695 B-chronic_disease
renal 7 12 1696 1701 I-chronic_disease
impairment 13 23 1702 1712 I-chronic_disease
( 24 25 1713 1714 O
calculated 25 35 1714 1724 O
creatinine 36 46 1725 1735 B-clinical_variable
clearance 47 56 1736 1745 I-clinical_variable
= 57 58 1746 1747 O
< 58 59 1747 1748 O
29 60 62 1749 1751 B-upper_bound
cc 63 65 1752 1754 I-upper_bound
/ 65 66 1754 1755 I-upper_bound
min 66 69 1755 1758 I-upper_bound
) 69 70 1758 1759 O

Total 0 5 1760 1765 B-treatment
( 6 7 1766 1767 I-treatment
T. 7 9 1767 1769 I-treatment
) 9 10 1769 1770 I-treatment
bilirubin 11 20 1771 1780 I-treatment
, 20 21 1780 1781 O
albumin 22 29 1782 1789 B-treatment
, 29 30 1789 1790 O
prothrombin 31 42 1791 1802 B-treatment
time 43 47 1803 1807 I-treatment
, 47 48 1807 1808 O
and 49 52 1809 1812 O
serum 53 58 1813 1818 B-treatment
creatinine 59 69 1819 1829 I-treatment
tests 70 75 1830 1835 O
can 76 79 1836 1839 O
be 80 82 1840 1842 O
done 83 87 1843 1847 O
within 88 94 1848 1854 O
14 95 97 1855 1857 B-upper_bound
days 98 102 1858 1862 I-upper_bound
of 103 105 1863 1865 O
study 106 111 1866 1871 O
enrollment 112 122 1872 1882 O
( 123 124 1883 1884 O
only 124 128 1884 1888 O
if 129 131 1889 1891 O
not 132 135 1892 1895 O
performed 136 145 1896 1905 O
in 146 148 1906 1908 O
the 149 152 1909 1912 O
last 153 157 1913 1917 B-upper_bound
14 158 160 1918 1920 I-upper_bound
days 161 165 1921 1925 I-upper_bound
) 165 166 1925 1926 O

childbearing 0 12 1927 1939 O
age 13 16 1940 1943 B-age
women 17 22 1944 1949 B-gender
who 23 26 1950 1953 O
are 27 30 1954 1957 O
not 31 34 1958 1961 O
on 35 37 1962 1964 O
birth 38 43 1965 1970 O
control 44 51 1971 1978 O

intend 0 6 1979 1985 B-pregnancy
to 7 9 1986 1988 I-pregnancy
become 10 16 1989 1995 I-pregnancy
pregnant 17 25 1996 2004 I-pregnancy
during 26 32 2005 2011 O
the 33 36 2012 2015 O
participation 37 50 2016 2029 O
of 51 53 2030 2032 O
the 54 57 2033 2036 O
study 58 63 2037 2042 O

